About our project

The problem we solve: The human population is becoming near-sighted at am alarming rate, due to young people spending many hours per day on smart devices such as phones, rather than outdoors playing. The resulting costs to individuals and society will be huge. The risk of blinding complications increases significantly with higher grades of myopia. Our goal is to prevent this global epidemic.

About our solution: We have developed proprietary optics that can be used by children and are designed to prevent the development of myopia (near-sightedness).

Reopia Optics’ key highlights include:

• The number of myopes globally will increase to 5 billion by 2050, with 1 billion of these being high myopes at risk for blinding complications. 
• Reopia Optics believes the best way to avert this worldwide epidemic is to intervene early.
  • The company is developing proprietary spectacle mounted optics that are designed to be worn by children (5-12 years old) who are experiencing emerging myopia.
  • The expected result is prevention of further eye growth that leads to myopia and associated complications.
• Our patent portfolio is strong, with 2 applications filed including in the PCT for global coverage.
• We have prototypes that demonstrate the key features of the invention.
• A key opinion leader in myopia prevention is on our Advisory Board.
• The innovation has been positively reviewed under NDA by R&D teams from several of the largest eye care companies in the world.
• The value proposition and customer profile has been validated through completion of a regional NSF funded iCorps program, and the proprietary technology has been positively vetted under NDA by some of the largest global strategics in this space.  They have asked to see pre-clinical and clinical data.
• The company is raising up to $1M of equity capital for optimization of our optical design, and to obtain pre-clinical proof-of-concept data.

About Our Company

How We Help Patients

Myopia has consequenes for patients.  The worst include blindness and visual disability.  At best, there are cosmetic issues, and potential discrimination.  Additionally, the lifeling financial burden of treating myopia is significant.

How We Help Physicians

Reopia glasses provide optometrists and ophthalmologists with a convenient, safe, and easy approach to help their patients avoid the risks and costs of progressive myopia.

Innovation Details

Intellectual Property Summary

We have filed 2 strong patents in the US PTO as well as PCT for international protection.

Clinical Information

The capital being raised will be used to embark on pre-clinical proof-of-concept data, optics optimization, and clinical studies.

Regulatory Status

The device will require an FDA study.  

How we will use the funds raised

Optimization of the optical design, conducting pre-clinical and clinical validation studies, and planning for FDA study.

Thank You

The global epidemic of myopia is just now being recognized as a major health threat, that will  have a major impact on quality of life and be very costly.  We aim to prevent this epidemic from worsening, and ultimatley prevent the world from becoming near sighted!

Investor Info

Market Size

The target market, just in the US, is children in the 5-12 year old age range, which is about 30 million potential patients.  We estimate that at least 10% of these children will be candidates for our treatment to prevent myopia, at a per unit sale price of $350, which is a >$1B market opportunity in the US alone.  The percent of children at risk for myopia progression is larger in Asia.

Projected 3 Year Growth

This is still TBD.  

Revenue Model

We will make money by selling our myopia prevention treatment primarily through optometrists to patients.  

Competitors

There are eye drops and contact lenses that purport to reduce myopia progression.  Both carry risks to the patient, are moderately effective, not approved for that intended use, and represent a burden for both patient and caregiver.  Our solution is worn as regular glasses, and are much safer and easier to use.

Traction

We have talked with a number of the largest eye care companies under NDA, and they all asked us to return with proof-of-concept data.

Due Diligence Docs

Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.

Send access request

Supporters

• 
  Mary Beth Arzac, MBA
  09/23/2019 - Liked the project.

Comments

Updates

No updates found .